- Home
- OPHC vs BIVI Comparison
OPHC vs BIVI Comparison
Compare OPHC & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPHC
- BIVI
- Stock Information
- Founded
- OPHC 2000
- BIVI 2013
- Country
- OPHC United States
- BIVI United States
- Employees
- OPHC N/A
- BIVI N/A
- Industry
- OPHC Major Banks
- BIVI Biotechnology: Pharmaceutical Preparations
- Sector
- OPHC Finance
- BIVI Health Care
- Exchange
- OPHC Nasdaq
- BIVI Nasdaq
- Market Cap
- OPHC 49.0M
- BIVI 49.8M
- IPO Year
- OPHC N/A
- BIVI N/A
- Fundamental
- Price
- OPHC $4.49
- BIVI $1.48
- Analyst Decision
- OPHC Hold
- BIVI Strong Buy
- Analyst Count
- OPHC 1
- BIVI 1
- Target Price
- OPHC $5.25
- BIVI $30.00
- AVG Volume (30 Days)
- OPHC 45.7K
- BIVI 596.3K
- Earning Date
- OPHC 02-05-2025
- BIVI 02-11-2025
- Dividend Yield
- OPHC N/A
- BIVI N/A
- EPS Growth
- OPHC 53.23
- BIVI N/A
- EPS
- OPHC 1.33
- BIVI N/A
- Revenue
- OPHC $37,091,000.00
- BIVI N/A
- Revenue This Year
- OPHC N/A
- BIVI N/A
- Revenue Next Year
- OPHC N/A
- BIVI N/A
- P/E Ratio
- OPHC $3.38
- BIVI N/A
- Revenue Growth
- OPHC 60.44
- BIVI N/A
- 52 Week Low
- OPHC $4.00
- BIVI $1.04
- 52 Week High
- OPHC $5.90
- BIVI $33.10
- Technical
- Relative Strength Index (RSI)
- OPHC 37.59
- BIVI 32.72
- Support Level
- OPHC $4.71
- BIVI $1.45
- Resistance Level
- OPHC $4.80
- BIVI $1.88
- Average True Range (ATR)
- OPHC 0.11
- BIVI 0.16
- MACD
- OPHC -0.01
- BIVI -0.01
- Stochastic Oscillator
- OPHC 0.00
- BIVI 5.08
About OPHC OptimumBank Holdings Inc.
OptimumBank Holdings Inc serves as a bank holding company for OptimumBank. The Bank provides a range of community banking services to individuals and corporate customers. Its services include demand interest-bearing and non-interest-bearing accounts, negotiable order of withdrawal account, money market deposit accounts, debit cards, and automated teller machines.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.